Literature DB >> 25676564

Role of apomorphine in the treatment of Parkinson's disease.

Allison Boyle1, William Ondo.   

Abstract

Current research shows that apomorphine is an effective treatment for symptoms of Parkinson's Disease (PD). The highly lipophilic structure allows apomorphine to cross cell membranes rapidly, leading to the rapid onset of action for on/off symptoms of PD. The use of apomorphine was limited in the past due to peripheral side effects, but with the advent of better delivery systems and medications to control side effects, apomorphine is better tolerated and more widely in use. The major delivery systems are continuous subcutaneous infusions and intermittent subcutaneous injections, but other delivery routes are under investigation. The purpose of this article is to discuss the current use of apomorphine, the current delivery systems and to discuss future research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25676564     DOI: 10.1007/s40263-014-0221-z

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  43 in total

1.  Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease.

Authors:  Peter A LeWitt; William G Ondo; Brenda Van Lunen; Peter B Bottini
Journal:  Clin Neuropharmacol       Date:  2009 Mar-Apr       Impact factor: 1.592

2.  Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations.

Authors:  A J Manson; H Hanagasi; K Turner; P N Patsalos; P Carey; N Ratnaraj; A J Lees
Journal:  Brain       Date:  2001-02       Impact factor: 13.501

3.  Role of subcutaneous apomorphine in parkinsonian voiding dysfunction.

Authors:  T J Christmas; P A Kempster; C R Chapple; J P Frankel; A J Lees; G M Stern; E J Milroy
Journal:  Lancet       Date:  1988 Dec 24-31       Impact factor: 79.321

4.  The pharmacokinetic and clinical effects of tolcapone on a single dose of sublingual apomorphine in Parkinson's disease.

Authors: 
Journal:  Parkinsonism Relat Disord       Date:  2000-10-01       Impact factor: 4.891

Review 5.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

6.  Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine.

Authors:  M Gassen; A Gross; M B Youdim
Journal:  Mov Disord       Date:  1998-07       Impact factor: 10.338

7.  [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].

Authors:  P Pollak; A S Champay; J M Gaio; M Hommel; A L Benabid; J Perret
Journal:  Rev Neurol (Paris)       Date:  1990       Impact factor: 2.607

Review 8.  Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.

Authors:  Carl E Clarke; Paul Worth; Donald Grosset; David Stewart
Journal:  Parkinsonism Relat Disord       Date:  2009-10-04       Impact factor: 4.891

Review 9.  Practical considerations in the use of apomorphine injectable.

Authors:  Annette Bowron
Journal:  Neurology       Date:  2004-03-23       Impact factor: 9.910

Review 10.  The pharmacological properties and therapeutic use of apomorphine.

Authors:  Samo Ribarič
Journal:  Molecules       Date:  2012-05-07       Impact factor: 4.411

View more
  12 in total

1.  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Authors:  Mark Dominic Latt; Simon Lewis; Olfat Zekry; Victor S C Fung
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

Review 2.  Advanced stages of PD: interventional therapies and related patient-centered care.

Authors:  Rejko Krüger; Rüdiger Hilker; Christian Winkler; Michael Lorrain; Matthias Hahne; Christoph Redecker; Paul Lingor; Wolfgang H Jost
Journal:  J Neural Transm (Vienna)       Date:  2015-07-03       Impact factor: 3.575

Review 3.  Therapy-resistant symptoms in Parkinson's disease.

Authors:  Ruxandra Julia Vorovenci; Roberta Biundo; Angelo Antonini
Journal:  J Neural Transm (Vienna)       Date:  2015-09-26       Impact factor: 3.575

Review 4.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

Review 5.  Mesenchymal Stem Cells-derived Exosomes: A New Possible Therapeutic Strategy for Parkinson's Disease?

Authors:  Helena Vilaça-Faria; António J Salgado; Fábio G Teixeira
Journal:  Cells       Date:  2019-02-02       Impact factor: 6.600

6.  Drugs-Induced Pathological Gambling: An Analysis of Italian Spontaneous Reporting System.

Authors:  Cristina Scavone; Barbara Stelitano; Concetta Rafaniello; Francesco Rossi; Liberata Sportiello; Annalisa Capuano
Journal:  J Gambl Stud       Date:  2020-03

Review 7.  Extracellular Vesicles as Nanotherapeutics for Parkinson's Disease.

Authors:  Loredana Leggio; Greta Paternò; Silvia Vivarelli; Francesca L'Episcopo; Cataldo Tirolo; Gabriele Raciti; Fabrizio Pappalardo; Carmela Giachino; Salvatore Caniglia; Maria Francesca Serapide; Bianca Marchetti; Nunzio Iraci
Journal:  Biomolecules       Date:  2020-09-16

8.  Apomorphine Reduces A53T α-Synuclein-Induced Microglial Reactivity Through Activation of NRF2 Signalling Pathway.

Authors:  Tony Heurtaux; Melanie Kirchmeyer; Eric Koncina; Paul Felten; Lorraine Richart; Oihane Uriarte Huarte; Herve Schohn; Michel Mittelbronn
Journal:  Cell Mol Neurobiol       Date:  2021-08-20       Impact factor: 4.231

Review 9.  Glutamic Acid Transporters: Targets for Neuroprotective Therapies in Parkinson's Disease.

Authors:  Xiang Li; Wenjun Wang; Jianghong Yan; Fancai Zeng
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

10.  Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease.

Authors:  Felix Agbo; Ryan L Crass; Yu-Yuan Chiu; Sunny Chapel; Gerald Galluppi; David Blum; Bradford Navia
Journal:  Clin Transl Sci       Date:  2021-05-02       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.